Fresenius Medical Care
FMS
20.69
-1.73
-7.72%
Fresenius Medical Care
US · FMS
#1333 by market cap
Listed 1970
20.69
-1.73
-7.72%
Live - 5344 symbols - heartbeat 337s ago
· 2026-10-08 07:00
Pre-market
20.76
+0.33%
After-hours
20.75
+0.29%
Overnight
20.61
-0.39%
- Market cap
- 11.01B
- P/E (TTM)i
- 11.14
- P/Bi
- 0.78
- EPSi
- 1.88
- Div yieldi
- 4.13%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on FMS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 1.84, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +1.51% YoY
Margins
- Gross margin
- 25.62%
- Operating margin
- 9.31%
- Net margin
- 4.98%
Key ratios & quality
- Enterprise valuei
- 17.08B
- PEG ratioi
- 0.84
- Altman Z-Scorei
- 1.84
PEG uses trailing P/E against the 3-year net income growth rate (13.26%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.55B | 17.48B | 17.86B | 17.62B | 19.40B | 19.45B | 19.34B | 19.63B |
| Gross profit | 5.15B | 5.40B | 5.54B | 4.77B | 4.89B | 4.93B | 4.76B | 5.03B |
| Selling & admin expenses | 2.89B | 3.03B | 3.13B | 2.77B | 3.17B | 3.20B | 3.14B | 3.03B |
| Research & development | 114.07M | 168.03M | 193.77M | 220.78M | 228.62M | 231.97M | 183.49M | 157.98M |
| Operating profit | 2.16B | 2.20B | 2.21B | 1.86B | 1.45B | 1.48B | 1.47B | 1.83B |
| Pretax profit | 2.74B | 1.84B | 1.94B | 1.57B | 1.22B | 1.03B | 1.06B | 1.51B |
| Tax | 511.08M | 401.61M | 500.56M | 352.83M | 324.95M | 300.56M | 316.06M | 320.97M |
| Net profit | 2.23B | 1.44B | 1.44B | 1.22B | 894.33M | 732.46M | 740.87M | 1.19B |
| Basic EPS | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 2 |
| Diluted EPS | 3.23 | 1.98 | 1.98 | 1.66 | 1.15 | 0.85 | 0.92 | 1.68 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.88B | 4.79B | 4.88B | 5.07B | 4.61B | 4.86B |
| Gross profit | 1.18B | 1.21B | 1.24B | 1.39B | 1.18B | 1.31B |
| Selling & admin expenses | 750.69M | 791.98M | 705.44M | 784.62M | 748.94M | 736.01M |
| Research & development | 43.48M | 38.12M | 37.75M | 38.63M | 38.31M | 39.63M |
| Operating profit | 381.73M | 379.78M | 501.72M | 548.98M | 375.56M | 537.27M |
| Pretax profit | 250.65M | 350.55M | 402.57M | 508.46M | 207.52M | 383.00M |
| Tax | 61.05M | 78.26M | 75.23M | 106.44M | 42.75M | 89.83M |
| Net profit | 189.61M | 272.30M | 327.34M | 402.02M | 164.76M | 293.17M |
| Basic EPS | 0 | 0 | 0 | 1 | 0 | 0 |
| Diluted EPS | 0.26 | 0.39 | 0.47 | 0.57 | 0.22 | 0.41 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 7.85B | 7.17B | 7.28B | 7.97B | 8.20B | 8.70B | 7.92B | 7.90B |
| Cash & ST investments | 2.25B | 1.14B | 1.24B | 1.62B | 1.43B | 1.51B | 1.45B | 1.82B |
| Inventory | 1.47B | 1.66B | 1.90B | 2.04B | 2.30B | 2.18B | 2.07B | 2.14B |
| Total assets | 26.24B | 32.93B | 31.69B | 34.37B | 35.75B | 33.93B | 33.57B | 31.00B |
| Total current liabilities | 6.27B | 7.06B | 6.06B | 7.26B | 6.47B | 6.11B | 5.66B | 6.25B |
| Short-term debt | 2.50B | 3.26B | 1.70B | 2.59B | 2.02B | 1.56B | 1.22B | 2.20B |
| Long-term debt | 5.05B | 6.46B | 6.80B | 6.65B | 7.17B | 6.96B | 6.26B | 5.69B |
| Total liabilities | 13,340,310,000.00 | 19,707,498,000.00 | 19,357,726,000.00 | 20,387,521,000.00 | 20,304,935,000.00 | 19,103,273,000.00 | 17,798,066,000.00 | 16,719,524,000.00 |
| Total equity | 12.90B | 13.23B | 12.33B | 13.98B | 15.45B | 14.83B | 15.77B | 14.28B |
| Retained earnings | 8.83B | 9.45B | 10.25B | 10.83B | 10.71B | 10.92B | 11.27B | 12.21B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 7.96B | 8.14B | 7.82B | 7.90B | 8.11B | 7.69B |
| Cash & ST investments | 1.49B | 2.19B | 1.81B | 1.82B | 1.62B | 1.45B |
| Inventory | 2.08B | 2.00B | 2.09B | 2.14B | 2.30B | 2.33B |
| Total assets | 32.74B | 31.29B | 30.89B | 31.00B | 31.47B | 31.29B |
| Total current liabilities | 5.45B | 5.66B | 5.76B | 6.25B | 6.73B | 7.18B |
| Short-term debt | 1.31B | 1.60B | 1.14B | 2.20B | 2.39B | 2.33B |
| Long-term debt | 6.15B | 6.33B | 6.32B | 5.69B | 5.74B | 5.82B |
| Total liabilities | 17,230,395,000.00 | 16,964,359,000.00 | 16,978,599,000.00 | 16,719,524,000.00 | 17,262,895,000.00 | 17,761,986,000.00 |
| Total equity | 15.50B | 14.33B | 13.91B | 14.28B | 14.20B | 13.53B |
| Retained earnings | 11.47B | 11.29B | 11.84B | 12.21B | 12.30B | 12.09B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.06B | 2.57B | 4.23B | 2.49B | 2.17B | 2.63B | 2.39B | 2.68B |
| Depreciation & amortization | 789.57M | 1.59B | 1.79B | 1.62B | 1.84B | 1.75B | 1.74B | 1.50B |
| Free cash flow | 1.00B | 1.44B | 3.18B | 1.64B | 1.44B | 1.94B | 1.69B | 1.77B |
| Dividends paid | -324.84M | -354.64M | -351.17M | -392.46M | -395.56M | -328.62M | -349.16M | -422.52M |
| Stock buybacks / issuance | -37.22M | -599.80M | -365.99M | -- | -- | 0 | 0 | -585.29M |
| Ending cash balance | 2.15B | 1.01B | 1.08B | 1.48B | 1.27B | 1.43B | 1.19B | 1.60B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 162.82M | 774.93M | 741.56M | 1.00B | 226.89M | 860.30M |
| Depreciation & amortization | 394.36M | 375.24M | 357.26M | 373.55M | 462.94M | 363.11M |
| Free cash flow | 17.06M | 620.55M | 549.35M | 578.67M | 36.82M | 619.90M |
| Dividends paid | -- | -- | 0 | 0 | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -151.12M | -434.17M | -347.33M | -144.64M |
| Ending cash balance | 1.08B | 1.72B | 1.26B | 1.60B | 1.24B | 1.06B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 18.37 | 10.12 | 10.05 | 8.11 | 5.05 | 3.61 | 3.82 | 7.02 |
| ROA %i | 7.89 | 4.05 | 3.60 | 2.93 | 1.92 | 1.43 | 1.59 | 3.03 |
| ROIC %i | 12.18 | 6.82 | 5.83 | 4.78 | 3.34 | 2.79 | 3.02 | 4.94 |
| 5-year avg ROE %i | 13.32 | 12.96 | 12.70 | 11.91 | 10.34 | 7.39 | 6.13 | 5.52 |
| EBIT margin %i | 19.25 | 13.34 | 13.14 | 10.93 | 8.14 | 7.49 | 7.57 | 9.66 |
| FCF / sales %i | 6.07 | 8.25 | 17.81 | 9.28 | 7.44 | 9.99 | 8.72 | 9.00 |
| Current ratioi | 1.25 | 1.02 | 1.20 | 1.10 | 1.27 | 1.42 | 1.40 | 1.26 |
| Quick ratioi | 0.96 | 0.73 | 0.80 | 0.76 | 0.85 | 0.91 | 0.95 | 0.88 |
| Debt / assetsi | 28.76 | 41.85 | 39.07 | 38.76 | 36.90 | 35.52 | 32.71 | 34.82 |
| LT debt / equityi | 42.91 | 88.01 | 95.26 | 84.53 | 79.89 | 77.01 | 66.96 | 64.60 |
| Interest coveragei | 7.10 | 4.75 | 5.72 | 5.45 | 4.39 | 3.43 | 3.60 | 4.93 |
| Revenue CAGR (3Y) %i | 2.30 | 1.79 | 0.14 | 2.11 | 3.54 | 2.89 | 3.15 | 0.39 |
| Net income CAGR (3Y) %i | 27.56 | 1.60 | -3.10 | -21.21 | -17.51 | -24.61 | -17.82 | 13.26 |
| FCF CAGR (3Y) %i | 3.44 | 12.93 | 36.63 | 17.63 | 0.03 | -15.14 | 1.04 | 6.95 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 4.37 | 4.82 | 5.41 | 7.02 | 6.84 | 7.26 |
| ROA %i | 1.84 | 2.01 | 2.27 | 3.03 | 2.94 | 3.00 |
| ROIC %i | 3.32 | 3.55 | 3.96 | 4.94 | 4.82 | 4.98 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.94 | 7.96 | 7.99 | 9.66 | 9.56 | 9.70 |
| FCF / sales %i | 8.77 | 10.49 | 9.05 | 9.00 | 9.22 | 9.19 |
| Current ratioi | 1.46 | 1.44 | 1.36 | 1.26 | 1.20 | 1.07 |
| Quick ratioi | 0.93 | 0.96 | 0.88 | 0.88 | 0.79 | 0.68 |
| Debt / assetsi | 33.06 | 35.23 | 33.91 | 34.82 | 35.05 | 35.03 |
| LT debt / equityi | 66.15 | 70.99 | 72.09 | 64.60 | 65.25 | 68.79 |
| Interest coveragei | 3.88 | 3.96 | 4.06 | 4.93 | 4.85 | 4.92 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Care Delivery is the largest reported line at 71.56% of revenue, across 4 reported segments.
- The next-largest line, Care Enablement, is a distant second at 28.21% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Care Delivery71.56%
Care Enablement28.21%
Value-Based Care11.03%
Quote time 2026-10-08 07:00:11 · For reference only, not investment advice and not tailored to your situation.